Pharming Group
PHAR
5 hedge funds and large institutions have $514K invested in Pharming Group in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
39% more capital invested
Capital invested by funds: $369K → $514K (+$145K)
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBCM
Silverberg Bernstein Capital Management
Armonk,
New York
|
+$58.7K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4.12K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$85 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.96K |
| 2 |
BlackRock
New York
|
-$2.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SBCM
1
Silverberg Bernstein Capital Management
Armonk,
New York
| $483K | +$58.7K | +6,887 | +17% |
|
|
2
Morgan Stanley
New York
| $26.2K | -$5.96K | -700 | -21% |
|
|
3
Osaic Holdings
Scottsdale,
Arizona
| $4.86K | +$4.12K | +483 | New |
|
|
FFA
4
Farther Finance Advisors
San Francisco,
California
| $111 | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $101 | +$85 | +10 | New |
|
|
6
BlackRock
New York
| – | -$2.69K | -326 | Closed |
|
PHAR Hedge Fund Activity: Q4 2024 in Review
5 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q4 2024, worth a combined $514K — up 39% from $369K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PHAR positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Silverberg Bernstein Capital Management, adding an estimated $58.7K. The largest seller was Morgan Stanley, cutting an estimated $5.96K.
- 5 institutional investors held Pharming Group (PHAR) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $514K of Pharming Group stock for Q4 2024, up 39% quarter-over-quarter.
- 2 funds opened new Pharming Group positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Pharming Group buyer in Q4 2024 was Silverberg Bernstein Capital Management, an estimated $58.7K added.
- The largest Pharming Group seller in Q4 2024 was Morgan Stanley, an estimated $5.96K sold.
Based on aggregated 13F filings for Q4 2024.